

9 November 2009

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000



**cyclo**medica  
**molecular**imaging  
**techneg**as

Cyclopharm Limited  
ABN 74 116 931 250  
Suite 630 Level 6  
1 Queens Road  
Melbourne Victoria 3004  
Australia  
T 61 3 9867 2811  
F 61 3 9820 5957  
[www.cyclopharm.com](http://www.cyclopharm.com)

### **Cyclotron delivered to Macquarie University Hospital**

Cyclopharm Limited (ASX: CYC) is pleased to announce that the company's first cyclotron was delivered to our production and research facility located at Macquarie University Hospital (MUH) during October 2009. The installation of the GE cyclotron represents the most critical step in completing the production site.

Cyclopharm's facility at MUH represents the first commercial radiopharmaceutical production centre to be located within a Sydney hospital. The site will be dedicated to the production of injectable radio-markers used in PET scanning. Along with filling an immediate demand for commercial PET isotopes, Cyclopharm will be engaged in research and development projects with researchers affiliated with the Australian Graduate School of Advanced Medicine, industry and our joint venture partners.

As previously advised, Cyclopharm will participate in a Joint Venture with Alfred Health Solutions to provide patients at MUH and neighbouring suburbs access to state of the art imaging facilities including Positron Emission Tomography (PET) scanning. PET is clinically proven to better identify the location and extent of certain active cancer cells in the body and is the fastest growing nuclear medicine diagnostic imaging modality in the world.

The Directors are delighted by this company milestone. Practical construction will be completed by the end of December 2009 with commissioning to take place early Q1 2010. The imaging centre is expected to be operational by the close of Q2 2010.

James McBrayer  
**Managing Director**

#### **Contact details:**

Mr James McBrayer  
Managing Director  
Cyclopharm Limited  
T: +61 2 9541 0411

## **Background**

### **Cyclopharm Limited**

Cyclopharm is a radiopharmaceutical company servicing the medical global medical community. The Company's mission is to enable nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

### **Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,500°C. The resultant gaseous substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

### **Positron Emission Tomography (PET)**

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed.

### **Macquarie University Hospital and the Macquarie University School of Advanced Medicine**

Macquarie University Hospital will establish a major medical precinct within the Macquarie University Research Park to complement the Allied Health teaching services offered by Macquarie University.

The Macquarie University Hospital will be a state of the art facility that will also deliver health education and research on site.